Free Trial

Anavex Life Sciences (AVXL) Financials

Anavex Life Sciences logo
$9.52 +0.07 (+0.69%)
As of 11:46 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Annual Income Statements for Anavex Life Sciences

Annual Income Statements for Anavex Life Sciences

This table shows Anavex Life Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
-48 -48 -43
Consolidated Net Income / (Loss)
-48 -48 -43
Net Income / (Loss) Continuing Operations
-48 -48 -43
Total Pre-Tax Income
-48 -47 -43
Total Operating Income
-51 -56 -53
Total Gross Profit
0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00
Total Operating Expenses
51 56 53
Selling, General & Admin Expense
13 12 11
Research & Development Expense
38 44 42
Total Other Income / (Expense), net
3.37 8.26 9.88
Interest Expense
-0.95 -6.52 -7.32
Interest & Investment Income
3.32 2.72 2.29
Other Income / (Expense), net
-0.90 -0.98 0.26
Income Tax Expense
0.36 0.01 0.00
Basic Earnings per Share
- ($0.60) ($0.52)
Weighted Average Basic Shares Outstanding
-0.62 79.79M 83.47M
Diluted Earnings per Share
- ($0.60) ($0.52)
Weighted Average Diluted Shares Outstanding
-0.62 79.79M 83.47M
Weighted Average Basic & Diluted Shares Outstanding
-0.62 82.09M 84.82M

Quarterly Income Statements for Anavex Life Sciences

This table shows Anavex Life Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Net Income / (Loss) Attributable to Common Shareholders
-12 -14 -13 -13 -11 -10 -8.62 -11 -12 -12 -12
Consolidated Net Income / (Loss)
-12 -14 -13 -13 -11 -10 -8.62 -11 -12 -12 -12
Net Income / (Loss) Continuing Operations
-12 -14 -13 -13 -11 -10 -8.62 -11 -12 -12 -12
Total Pre-Tax Income
-12 -14 -13 -13 -11 -10 -8.62 -10 -12 -12 -12
Total Operating Income
-12 -15 -15 -14 -14 -13 -11 -13 -15 -14 -14
Total Gross Profit
0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue
0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue
0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses
12 15 15 14 14 13 11 13 15 14 14
Selling, General & Admin Expense
3.19 3.90 3.32 2.88 3.25 2.59 2.69 2.79 2.86 2.78 3.15
Research & Development Expense
9.27 11 12 11 10 10 8.68 9.73 12 12 10
Total Other Income / (Expense), net
0.18 1.20 2.39 1.13 2.29 2.44 2.76 2.08 2.45 2.59 1.48
Interest Expense
-0.23 -0.70 -1.27 -1.47 -1.83 -1.96 -2.01 -1.76 -1.86 -1.70 -1.39
Interest & Investment Income
0.68 0.99 0.73 0.75 0.57 0.67 0.59 0.47 0.53 0.70 0.41
Other Income / (Expense), net
-0.73 -0.50 0.39 -1.08 -0.10 -0.19 0.16 -0.15 0.07 0.19 -0.33
Basic Earnings per Share
- - - ($0.17) ($0.14) - ($0.11) ($0.13) ($0.14) - ($0.14)
Weighted Average Basic Shares Outstanding
-0.16 -0.62 77.98M 78.30M 80.88M 79.79M 82.08M 82.46M 84.54M 83.47M 84.81M
Diluted Earnings per Share
- - - ($0.17) ($0.14) - ($0.11) ($0.13) ($0.14) - ($0.14)
Weighted Average Diluted Shares Outstanding
-0.16 -0.62 77.98M 78.30M 80.88M 79.79M 82.08M 82.46M 84.54M 83.47M 84.81M
Weighted Average Basic & Diluted Shares Outstanding
77.44M -0.62 77.98M 78.30M -0.14 82.09M 82.11M 84.64M 84.80M 84.82M 85.06M

Annual Cash Flow Statements for Anavex Life Sciences

This table details how cash moves in and out of Anavex Life Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents
-2.95 1.87 -19
Net Cash From Operating Activities
-24 -28 -31
Net Cash From Continuing Operating Activities
-24 -28 -31
Net Income / (Loss) Continuing Operations
-48 -48 -43
Consolidated Net Income / (Loss)
-48 -48 -43
Non-Cash Adjustments To Reconcile Net Income
18 17 9.36
Changes in Operating Assets and Liabilities, net
5.36 2.51 2.83
Net Cash From Investing Activities
0.00 0.00 0.00
Net Cash From Continuing Investing Activities
0.00 0.00 0.00
Net Cash From Financing Activities
21 30 12
Net Cash From Continuing Financing Activities
21 30 12
Issuance of Common Equity
21 28 11
Other Financing Activities, net
1.01 1.78 0.69

Quarterly Cash Flow Statements for Anavex Life Sciences

This table details how cash moves in and out of Anavex Life Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Net Change in Cash & Equivalents
-0.14 -4.04 -5.54 9.85 1.35 -3.79 -7.26 -4.38 -0.63 -6.57 -11
Net Cash From Operating Activities
-7.05 -4.04 -5.79 -8.49 -7.65 -5.85 -7.32 -12 -5.18 -6.66 -12
Net Cash From Continuing Operating Activities
-7.05 -4.04 -5.79 -8.49 -7.65 -5.85 -7.32 -12 -5.18 -6.66 -12
Net Income / (Loss) Continuing Operations
-12 -14 -13 -13 -11 -10 -8.62 -11 -12 -12 -12
Consolidated Net Income / (Loss)
-12 -14 -13 -13 -11 -10 -8.62 -11 -12 -12 -12
Non-Cash Adjustments To Reconcile Net Income
3.99 6.04 5.35 4.82 3.87 3.19 2.29 2.65 2.43 2.00 2.06
Changes in Operating Assets and Liabilities, net
1.33 4.20 1.83 -0.20 -0.24 1.11 -0.98 -3.76 4.61 2.97 -2.06
Net Cash From Investing Activities
- - 0.00 - - - 0.00 - - - 0.00
Net Cash From Continuing Investing Activities
- - 0.00 - - - 0.00 - - - 0.00
Net Cash From Financing Activities
6.91 0.00 0.26 18 9.00 2.06 0.06 7.28 4.55 0.09 0.71
Net Cash From Continuing Financing Activities
6.91 0.00 0.26 18 9.00 2.06 0.06 7.28 4.55 0.09 0.71
Other Financing Activities, net
0.51 -0.00 0.26 0.18 0.47 0.87 0.06 0.10 0.44 0.09 0.71

Annual Balance Sheets for Anavex Life Sciences

This table presents Anavex Life Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets
153 154 136
Total Current Assets
153 152 133
Cash & Equivalents
149 151 132
Prepaid Expenses
0.35 0.65 0.93
Plant, Property, & Equipment, net
0.00 0.00 0.00
Total Noncurrent Assets
0.00 2.71 2.45
Noncurrent Note & Lease Receivables
- 2.71 2.45
Total Liabilities & Shareholders' Equity
153 154 136
Total Liabilities
10 13 15
Total Current Liabilities
9.77 12 14
Accounts Payable
3.83 4.32 9.63
Accrued Expenses
5.95 7.30 4.84
Total Noncurrent Liabilities
0.44 0.92 0.84
Other Noncurrent Operating Liabilities
0.44 - 0.84
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
142 142 120
Total Preferred & Common Equity
142 142 120
Preferred Stock
0.00 0.00 0.00
Total Common Equity
142 142 120
Common Stock
388 435 456
Retained Earnings
-246 -293 -336

Quarterly Balance Sheets for Anavex Life Sciences

This table presents Anavex Life Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Total Assets
160 148 159 158 148 145 142 124
Total Current Assets
160 148 159 156 145 141 142 121
Cash & Equivalents
153 144 153 155 144 139 139 121
Prepaid Expenses
0.46 0.66 0.98 0.83 0.76 1.35 1.06 0.71
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
0.00 0.00 0.00 2.17 3.55 3.79 0.00 2.56
Noncurrent Note & Lease Receivables
- - - 2.17 3.55 3.79 - 2.56
Total Liabilities & Shareholders' Equity
160 148 159 158 148 145 142 124
Total Liabilities
9.48 13 14 11 12 9.56 12 13
Total Current Liabilities
9.48 12 13 10 12 8.64 11 12
Accounts Payable
3.13 5.29 6.28 4.15 4.29 3.73 3.50 4.57
Accrued Expenses
5.91 7.04 6.82 5.99 7.29 4.92 7.33 7.73
Total Noncurrent Liabilities
0.00 0.92 0.92 0.92 0.92 0.92 0.92 0.83
Other Noncurrent Operating Liabilities
- 0.92 0.92 0.92 0.92 0.92 0.92 0.83
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
151 135 145 147 136 135 130 111
Total Preferred & Common Equity
151 135 145 147 136 135 130 111
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
151 135 145 147 136 135 130 111
Common Stock
382 394 417 430 437 447 454 459
Retained Earnings
-231 -259 -272 -283 -302 -312 -324 -348

Annual Metrics and Ratios for Anavex Life Sciences

This table displays calculated financial ratios and metrics derived from Anavex Life Sciences' official financial filings.

Metric 2022 2023 2024
Growth Metrics
- - -
Revenue Growth
0.00% 0.00% 0.00%
EBITDA Growth
-22.92% -9.34% 7.27%
EBIT Growth
-22.92% -9.34% 7.27%
NOPAT Growth
-21.39% -9.36% 5.16%
Net Income Growth
-26.56% 0.99% 9.48%
EPS Growth
0.00% 0.00% 13.33%
Operating Cash Flow Growth
20.23% -14.63% -10.89%
Free Cash Flow Firm Growth
-0.63% -20.49% 6.19%
Invested Capital Growth
-416.97% -37.57% -30.00%
Revenue Q/Q Growth
0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-6.67% 4.93% -2.55%
EBIT Q/Q Growth
-6.67% 4.93% -2.55%
NOPAT Q/Q Growth
-6.32% 4.51% -3.29%
Net Income Q/Q Growth
-5.66% 8.02% -3.55%
EPS Q/Q Growth
0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
13.03% -6.95% -2.70%
Free Cash Flow Firm Q/Q Growth
3.83% -3.55% 1.89%
Invested Capital Q/Q Growth
-170.71% -13.76% -32.86%
Profitability Metrics
- - -
Gross Margin
0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00%
Tax Burden Percent
100.75% 100.01% 100.00%
Interest Burden Percent
91.77% 83.72% 81.73%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00%
Return on Equity (ROE)
-32.72% -33.41% -32.81%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-32.72% -33.41% -32.81%
Return on Equity Simple (ROE_SIMPLE)
-33.67% -33.49% -35.76%
Net Operating Profit after Tax (NOPAT)
-36 -39 -37
NOPAT Margin
0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-8.16% -5.65% -4.23%
Return On Investment Capital (ROIC_SIMPLE)
- -27.51% -30.78%
Cost of Revenue to Revenue
0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-52 -57 -53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-52 -57 -53
Valuation Ratios
- - -
Price to Book Value (P/BV)
5.65 3.78 4.00
Price to Tangible Book Value (P/TBV)
5.65 3.78 4.00
Price to Revenue (P/Rev)
0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00
Financial Leverage
-1.03 -1.06 -1.08
Leverage Ratio
1.07 1.08 1.11
Compound Leverage Factor
0.98 0.90 0.90
Debt to Total Capital
0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00
Altman Z-Score
45.00 22.91 15.18
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
15.63 13.06 9.20
Quick Ratio
15.27 13.00 9.14
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-30 -37 -34
Operating Cash Flow to CapEx
0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00
Efficiency Ratios
- - -
Asset Turnover
0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00
Capital & Investment Metrics
- - -
Invested Capital
-6.67 -9.17 -12
Invested Capital Turnover
0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-5.38 -2.51 -2.75
Enterprise Value (EV)
655 386 349
Market Capitalization
804 537 482
Book Value per Share
$1.83 $1.73 $1.42
Tangible Book Value per Share
$1.83 $1.73 $1.42
Total Capital
142 142 120
Total Debt
0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00
Net Debt
-149 -151 -132
Capital Expenditures (CapEx)
0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-6.22 -11 -14
Debt-free Net Working Capital (DFNWC)
143 140 119
Net Working Capital (NWC)
143 140 119
Net Nonoperating Expense (NNE)
12 8.48 5.99
Net Nonoperating Obligations (NNO)
-149 -151 -132
Total Depreciation and Amortization (D&A)
0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
$0.00 $0.00 ($0.52)
Adjusted Weighted Average Basic Shares Outstanding
77.96M 82.09M 83.47M
Adjusted Diluted Earnings per Share
$0.00 $0.00 ($0.52)
Adjusted Weighted Average Diluted Shares Outstanding
77.96M 82.09M 83.47M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
76.91M 82.09M 84.82M
Normalized Net Operating Profit after Tax (NOPAT)
-36 -39 -37
Normalized NOPAT Margin
0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00%
Debt Service Ratios
- - -
EBIT to Interest Expense
0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
-1.47% 0.00% 0.00%

Quarterly Metrics and Ratios for Anavex Life Sciences

This table displays calculated financial ratios and metrics derived from Anavex Life Sciences' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-14.54% -25.88% -28.50% -35.74% -3.34% 18.64% 25.15% 17.04% -7.56% -10.18% -24.02%
EBIT Growth
-14.54% -25.88% -28.50% -35.74% -3.34% 18.64% 25.15% 17.04% -7.56% -10.18% -24.02%
NOPAT Growth
-9.30% -24.74% -31.22% -23.18% -8.61% 17.23% 26.04% 11.78% -8.85% -13.32% -19.46%
Net Income Growth
-21.49% -21.95% -19.20% -25.57% 8.79% 29.00% 33.53% 19.54% -8.28% -14.53% -40.47%
EPS Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 23.53% 0.00% 0.00% -27.27%
Operating Cash Flow Growth
6.22% 47.31% -65.50% 11.94% -8.50% -44.63% -26.30% -37.31% 32.31% -13.83% -65.62%
Free Cash Flow Firm Growth
36.47% 42.78% -57.20% 60.31% 41.97% -19.34% -17.34% -356.45% -142.72% -14.68% 5.17%
Invested Capital Growth
-494.41% -416.97% -77.83% -629.83% -227.38% -37.57% 3.62% 46.66% -11.32% -30.00% -20.39%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-17.24% -19.62% 4.98% -1.86% 10.74% 5.82% 12.59% -13.76% -15.73% 3.53% 1.61%
EBIT Q/Q Growth
-17.24% -19.62% 4.98% -1.86% 10.74% 5.82% 12.59% -13.76% -15.73% 3.53% 1.61%
NOPAT Q/Q Growth
-8.15% -22.68% -0.65% 7.76% 4.64% 6.50% 10.06% -10.86% -17.65% 2.67% 5.19%
Net Income Q/Q Growth
-18.49% -15.55% 9.23% -1.04% 13.94% 10.05% 15.02% -22.32% -15.82% 4.86% -4.23%
EPS Q/Q Growth
0.00% 0.00% 0.00% 0.00% 17.65% 0.00% 0.00% 0.00% -7.69% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
26.83% 42.67% -43.27% -46.51% 9.85% 23.57% -25.12% -59.28% 55.56% -28.53% -82.04%
Free Cash Flow Firm Q/Q Growth
4.34% 20.25% -32.47% 60.73% -39.85% -64.02% -30.26% -53.87% 25.63% 22.50% -7.71%
Invested Capital Q/Q Growth
-116.50% -170.71% -27.46% 2.30% 2.88% -13.76% 10.71% 45.93% -102.69% -32.86% 17.31%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.72% 101.49% 99.85% 100.38% 100.36% 99.37% 100.00% 101.01% 99.45% 98.95% 100.00%
Interest Burden Percent
93.08% 89.23% 86.65% 85.50% 82.45% 79.53% 76.83% 82.41% 83.76% 83.02% 87.02%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-29.50% -32.72% -35.57% -35.47% -34.72% -33.41% -31.88% -28.98% -30.03% -32.81% -37.72%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-29.50% -32.72% -35.57% -35.47% -34.72% -33.41% -31.88% -28.98% -30.03% -32.81% -37.72%
Return on Equity Simple (ROE_SIMPLE)
-30.12% 0.00% -37.05% -36.33% -35.19% 0.00% -31.83% -30.08% -32.00% 0.00% -41.92%
Net Operating Profit after Tax (NOPAT)
-8.72 -11 -11 -9.93 -9.47 -8.86 -7.96 -8.76 -10 -10 -9.51
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-2.35% -2.38% -1.49% -2.07% -1.17% -0.86% -0.46% -1.22% -1.30% -1.12% -1.96%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - -6.24% -5.87% - - -8.34% -8.58%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-13 -16 -15 -15 -14 -13 -11 -13 -15 -14 -14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-13 -16 -15 -15 -14 -13 -11 -13 -15 -14 -14
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
5.14 5.65 5.34 4.61 4.48 3.78 5.63 3.10 2.75 4.00 8.21
Price to Tangible Book Value (P/TBV)
5.14 5.65 5.34 4.61 4.48 3.78 5.63 3.10 2.75 4.00 8.21
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.01 -1.03 -1.05 -1.03 -1.04 -1.06 -1.06 -1.05 -1.06 -1.08 -1.07
Leverage Ratio
1.06 1.07 1.08 1.07 1.07 1.08 1.10 1.08 1.08 1.11 1.10
Compound Leverage Factor
0.99 0.96 0.94 0.92 0.88 0.86 0.84 0.89 0.91 0.92 0.96
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
47.85 45.78 31.02 27.01 33.98 23.85 34.61 24.02 15.79 16.12 38.39
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
16.89 15.63 12.03 12.15 15.35 13.06 12.48 16.29 13.06 9.20 9.88
Quick Ratio
16.15 15.27 11.65 11.71 15.27 13.00 12.42 16.13 12.80 9.14 9.82
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-6.67 -5.32 -7.05 -2.77 -3.87 -6.35 -8.27 -13 -9.40 -7.28 -7.84
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-2.46 -6.67 -8.50 -8.30 -8.06 -9.17 -8.19 -4.43 -8.98 -12 -9.86
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-2.05 -5.38 -3.72 -7.16 -5.60 -2.51 0.31 3.87 -0.91 -2.75 -1.67
Enterprise Value (EV)
622 655 578 515 502 386 619 279 218 349 790
Market Capitalization
775 804 722 669 657 537 763 418 357 482 911
Book Value per Share
$1.95 $1.83 $1.73 $1.86 $1.82 $1.73 $1.65 $1.64 $1.53 $1.42 $1.31
Tangible Book Value per Share
$1.95 $1.83 $1.73 $1.86 $1.82 $1.73 $1.65 $1.64 $1.53 $1.42 $1.31
Total Capital
151 142 135 145 147 142 136 135 130 120 111
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-153 -149 -144 -153 -155 -151 -144 -139 -139 -132 -121
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-2.46 -6.22 -7.58 -7.39 -9.31 -11 -11 -7.30 -8.06 -14 -12
Debt-free Net Working Capital (DFNWC)
151 143 136 146 146 140 133 132 131 119 109
Net Working Capital (NWC)
151 143 136 146 146 140 133 132 131 119 109
Net Nonoperating Expense (NNE)
3.65 3.59 2.20 3.17 1.81 1.29 0.66 1.78 1.90 1.58 2.60
Net Nonoperating Obligations (NNO)
-153 -149 -144 -153 -155 -151 -144 -139 -139 -132 -121
Total Depreciation and Amortization (D&A)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.16) $0.00 ($0.17) ($0.17) $0.00 $0.00 $0.00 ($0.13) ($0.14) $0.00 ($0.14)
Adjusted Weighted Average Basic Shares Outstanding
77.94M -1.00 78.03M 80.84M 81.95M 79.79M 82.11M 82.46M 84.54M 83.47M 84.81M
Adjusted Diluted Earnings per Share
($0.16) $0.00 ($0.17) ($0.17) $0.00 $0.00 $0.00 ($0.13) ($0.14) $0.00 ($0.14)
Adjusted Weighted Average Diluted Shares Outstanding
77.94M -1.00 78.03M 80.84M 81.95M 79.79M 82.11M 82.46M 84.54M 83.47M 84.81M
Adjusted Basic & Diluted Earnings per Share
($0.16) $0.00 ($0.17) ($0.17) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
77.44M -1.00 77.98M 78.30M 80.88M 82.09M 82.11M 84.64M 84.80M 84.82M 85.06M
Normalized Net Operating Profit after Tax (NOPAT)
-8.72 -11 -11 -9.93 -9.47 -8.86 -7.96 -8.76 -10 -10 -9.51
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% -1.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Anavex Life Sciences' Financials

When does Anavex Life Sciences's financial year end?

According to the most recent income statement we have on file, Anavex Life Sciences' fiscal year ends in September. Their fiscal year 2024 ended on September 30, 2024.

How has Anavex Life Sciences' net income changed over the last 2 years?

Anavex Life Sciences' net income appears to be on a downward trend, with a most recent value of -$43.00 million in 2024, falling from -$47.98 million in 2022. The previous period was -$47.51 million in 2023.

What is Anavex Life Sciences's operating income?
Anavex Life Sciences's total operating income in 2024 was -$52.88 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $52.88 million
How has Anavex Life Sciences revenue changed over the last 2 years?

Over the last 2 years, Anavex Life Sciences' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Anavex Life Sciences have?

Anavex Life Sciences' total liabilities were at $15.30 million at the end of 2024, a 22.1% increase from 2023, and a 49.8% increase since 2022.

How much cash does Anavex Life Sciences have?

In the past 2 years, Anavex Life Sciences' cash and equivalents has ranged from $132.19 million in 2024 to $151.02 million in 2023, and is currently $132.19 million as of their latest financial filing in 2024.

How has Anavex Life Sciences' book value per share changed over the last 2 years?

Over the last 2 years, Anavex Life Sciences' book value per share changed from 1.83 in 2022 to 1.42 in 2024, a change of -22.4%.



This page (NASDAQ:AVXL) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners